ISF-35

N/A

Report date: 2023/05/05 17:37:10

Base Information

Drug NameISF-35
Drug Alias NameAdenovirus-CD 154Ad-ISF35 transduced CLL B-cellsImmune Stimulatory Factor 35Ad-CD154Ad-ISF35 +[6] 
ClassificationBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionTumor necrosis factor receptor superfamily member 5 inhibitors
TargetsTumor necrosis factor receptor superfamily member 5
Therapy Area/IndicationsMelanomaLymphoma, Mantle-CellLymphoma, Follicular +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMemgen Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMemgen LlcThe University Of Texas MD Anderson Cancer CenterUniversity Of California San Diego
Active IndicationsN/A
Inactive IndicationsMelanomaLymphoma, Mantle-CellLymphoma, Follicular +[6] 

Other Information

ATC CodeN/A
Related LinksN/A